Previous Close | 0.4600 |
Open | 0.4528 |
Bid | 0.4380 x 1300 |
Ask | 0.4400 x 4000 |
Day's Range | 0.3725 - 0.4800 |
52 Week Range | 0.1810 - 1.8600 |
Volume | |
Avg. Volume | 2,271,448 |
Market Cap | 69.204M |
Beta (5Y Monthly) | 2.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3530 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.17 |
Subscribe to Yahoo Finance Plus to view Fair Value for TRVN
CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of Neurotherapeutics titled “A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain” by Eugene R. Viscusi, M.D., Director of Acute Pain Management at Jefferson He
CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, and Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held in New York on June 15 - 16, 2022. Fires
CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry Shin, CFO, will be participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022. H.C. Wainwright Global Investment Conference (Hybrid Conference) Date: Tuesday, May 24